MedTrace Logo

Coffee Intake Biomarker Validation and Association With Respiratory Diseases

NCT07391696 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-06

No results posted yet for this study

Summary

This proposed project aims to identify and validate biomarkers of coffee exposure in the Singapore population, and assess the association between coffee consumption (via biomarker measurements) and risk of respiratory diseases in a prospective multi-ethnic cohort in Singapore.

Specific Aim 1: To identify and quantify urinary/serum metabolite changes that are associated with coffee consumption in a dose-response intervention study.

Conditions

  • Coffee

Interventions

DIETARY_SUPPLEMENT

Coffee A

Week 1: coffee A ≤10 g coffee powder for low dose Week 2: non-coffee consumption (post-consumption kinetics) Week 3: coffee A ≤20 g coffee powder for medium dose Week 4: non-coffee consumption (post-consumption kinetics) Week 5: coffee A ≤40 g coffee powder for high dose Week 6: non-coffee consumption (post-consumption kinetics)

DIETARY_SUPPLEMENT

Coffee B

Week 7: coffee B ≤40 g coffee powder for high dose Week 8: non-coffee consumption (post-consumption kinetics)

DIETARY_SUPPLEMENT

Tea

Week 9: washout Week 10: tea (control) Week 11: non-coffee consumption (post-consumption kinetics)

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-12-31
Completion
2026-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07391696 on ClinicalTrials.gov